VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 43 filers reported holding VERONA PHARMA PLC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $72,821,407 | -20.0% | 4,467,571 | +3.8% | 0.02% | -11.8% |
Q2 2023 | $90,971,825 | +37.6% | 4,303,303 | +30.7% | 0.02% | +30.8% |
Q1 2023 | $66,092,778 | -24.4% | 3,291,473 | -1.6% | 0.01% | -27.8% |
Q4 2022 | $87,440,649 | +104.8% | 3,346,370 | -19.9% | 0.02% | +100.0% |
Q3 2022 | $42,691,000 | +166.2% | 4,177,276 | +9.1% | 0.01% | +200.0% |
Q2 2022 | $16,039,000 | -14.9% | 3,828,149 | +1.3% | 0.00% | 0.0% |
Q1 2022 | $18,856,000 | -41.9% | 3,778,785 | -21.8% | 0.00% | -40.0% |
Q4 2021 | $32,470,000 | +38.0% | 4,831,988 | +12.5% | 0.01% | +25.0% |
Q3 2021 | $23,531,000 | -8.0% | 4,294,038 | +9.8% | 0.00% | 0.0% |
Q2 2021 | $25,584,000 | -19.4% | 3,911,840 | +3.0% | 0.00% | -33.3% |
Q1 2021 | $31,753,000 | +264.1% | 3,798,141 | +204.9% | 0.01% | +200.0% |
Q4 2020 | $8,720,000 | – | 1,245,699 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |